Patents by Inventor Michael David Barker

Michael David Barker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS
    Publication number: 20140005188
    Abstract: A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.
    Type: Application
    Filed: March 8, 2012
    Publication date: January 2, 2014
    Applicant: GLAXO GROUP LIMITED
    Inventors: Francis Louis Atkinson, Stephen John Atkinson, Michael David Barker, Clement Douault, Neil Stuart Garton, John Liddle, Vipulkumar Kantibhai Patel, Alexander G. Preston, Tracy Jane Shipley, David Matthew Wilson, Robert J. Watson
  • 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS
    Publication number: 20130040984
    Abstract: The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.
    Type: Application
    Filed: April 27, 2011
    Publication date: February 14, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Francis Louis Atkinson, Michael David Barker, Clement Douault, Neil Stuart Garton, John Liddle, Vipulkumar Kantibhai Patel, Alexander George Steven Preston, David Matthew Wilson
  • NOVEL COMPOUNDS
    Publication number: 20120232061
    Abstract: A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 13, 2012
    Applicant: GLAXO GROUP LIMITED
    Inventors: Francis Louis Atkinson, Michael David Barker, John Liddle, David Matthew Wilson
  • Purine derivatives as agonists of the adenosine A2A receptor
    Patent number: 7985740
    Abstract: The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: July 26, 2011
    Assignee: Glaxo Group Limited
    Inventors: David George Allen, Michael David Barker, Richard Peter Charles Cousins
  • PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS
    Publication number: 20100179139
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: May 29, 2008
    Publication date: July 15, 2010
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS
    Publication number: 20100035917
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: February 11, 2010
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • Quinoline Derivatives As Phosphodiesterase Inhibitors
    Publication number: 20090312325
    Abstract: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Application
    Filed: May 29, 2009
    Publication date: December 17, 2009
    Inventors: Ian Robert Baldwin, Michael David Barker, Anthony William Dean, Colin David Eldred, Brian Evans, Sharon Lisa Gough, Stephen Barry Guntrip, Julie Nicole Hamblin, Stuart Holman, Paul Jones, Mika Kristian Lindvall, Christopher James Lunniss, Tracy Jane Redfern, Alison Judith Redgrave, John Edward Robinson, Michael Woodrow
  • Quinoline derivatives as phosphodiesterase inhibitors
    Patent number: 7572915
    Abstract: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: August 11, 2009
    Assignee: Glaxo Group Limited
    Inventors: Michael David Barker, Anthony William Dean, Brian Evans, Stuart Holman, Michael Woodrow
  • Quinoline derivatives as phosphodiesterase inhibitors
    Patent number: 7566786
    Abstract: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: July 28, 2009
    Assignee: Glaxo Group Limited
    Inventors: Ian Robert Baldwin, Michael David Barker, Anthony William Dean, Colin David Eldred, Brian Evans, Sharon Lisa Gough, Stephen Barry Guntrip, Julie Nicole Hamblin, Stuart Holman, Paul Jones, Mika Kristian Lindvall, Christopher James Lunniss, Tracy Jane Redfern, Alison Judith Redgrave, John Edward Robinson, Michael Woodrow
  • Purine Derivatives as Agonists of the Adenosine A2a Receptor
    Publication number: 20080214581
    Abstract: A compound of formula (I): wherein R1-R3 are as defined in the specification, and compositions, combinations, and methods of manufacture, and methods of treatment of inflammatory diseases, using the same.
    Type: Application
    Filed: July 17, 2006
    Publication date: September 4, 2008
    Inventors: David George Allen, Michael David Barker, Richard Peter Charles Cousins
  • Phenyl-Pyrazole Derivatives as Non-Steroidal Glucocorticoid Receptor Ligands
    Publication number: 20080207725
    Abstract: A compound of formula (I): wherein A represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; and R1 and R2 each independently represent hydrogen, fluorine or chlorine; or a physiologically functional derivative thereof.
    Type: Application
    Filed: June 27, 2006
    Publication date: August 28, 2008
    Inventors: Michael David Barker, David House, Haydn Terence Jones, Simon John Fawcett MacDonald, Iain McFarlane Mclay
  • NOVEL COMPOUNDS
    Publication number: 20080176891
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: July 24, 2008
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • NOVEL COMPOUNDS
    Publication number: 20080146606
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: June 19, 2008
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
    Patent number: 6528494
    Abstract: There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 4, 2003
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, IV, Joanna Victoria Geden
  • 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
    Patent number: 6426337
    Abstract: There are provided according to the invention novel compounds of formula (I) wherein R1, R2, and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: July 30, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, IV, Joanna Victoria Geden
  • 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
    Publication number: 20020086850
    Abstract: There are provided according to the invention novel compounds of formula I 1
    Type: Application
    Filed: December 19, 2001
    Publication date: July 4, 2002
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, Joanna Victoria Geden